Interesting recent posts. When we talk of gene therapy as a impending threat, how does cost of gene therapy compare to that of NZ2591? Is advantage of gene therapy that it is a cure rather than a treatment? I guess this where the importance of HIE to longer-term sales revenue is greater than most other indications where genetic "fault" is the cause. I wonder if the market is across that yet? The world of science is certainly very dynamic.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.55 |
Change
0.345(2.43%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $14.23 | $14.71 | $14.23 | $440.1K | 30.62K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 228 | $14.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.58 | 79 | 2 |
View Market Depth
| Last trade - 10.04am 30/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |